Introduction

 

Lung cancer is the second most common cancer of all cancers in both men and women in the United States after skin cancer. An estimated 222,520 adults will be diagnosed with the disease in 2010, according to the American Cancer Society.

Lung cancer starts when abnormal cells in the tissues of the lung, usually in the cells that line the air passages, begin to grow out of control. A lump of cancer cells (also called a malignant tumor, mass, nodule, or lesion) then forms.  There are two major types of lung cancer—non-small cell lung cancer (NSCLC) and small cell lung cancer. It is important that the type (non-small cell versus small cell) be determined because each type is usually treated differently.

Non-small cell lung cancer is more common than small cell lung cancer, and it generally grows and spreads more slowly.

Small cell lung cancer grows more quickly than non-small cell lung cancer and is more likely to spread to other organs in the body.

Other names for lung cancer include pulmonary carcinoma, bronchial carcinoma, and bronchoalveolar cell carcinoma. “Pulmonary” means “related to the lung” and comes from the Latin word for lung (pulmo). “Bronchoalveolar” describes the small lung structures that branch out from the bronchi (the main airways of the lungs).

The leading cause of lung cancer is smoking tobacco, which causes more than 90 percent of all lung cancers. However, not all people who smoke develop lung cancer, and not all cases of lung cancer are caused by smoking. Other risk factors for lung cancer include breathing secondary smoke (smoke from other people’s tobacco use), smoking marijuana, and exposure to asbestos or other harmful agents, such as radioactive substances, arsenic, vinyl, chloride, mustard gas, radon gas, or diesel exhaust.

This content was last reviewed August 15, 2010 by Dr. Reshma L. Mahtani.
Latest Lung Cancer News
US FDA panel votes against wider use of Amgen drug

February 8, 2012 — WASHINGTON (Reuters) - An advisory panel on Wednesday recommended that U.S. health regulators reject the use of Amgen Inc's drug Xgeva to delay the spread of prostate cancer to the bone, dimming the chance of a wider use for one of the company's key growth drivers.

US consumers want tougher probe of engineered salmon

February 8, 2012 — WASHINGTON (Reuters) - Three U.S. consumer groups petitioned the Food and Drug Administration on Tuesday to subject a new genetically engineered salmon to a more rigorous review process than is now in place before the fish can be approved as safe to eat.

Male smokers lose brain function faster as they age

February 6, 2012 — LONDON (Reuters) - Men who smoke suffer a more rapid decline in brain function as they age than their non-smoking counterparts, with their cognitive decline as rapid as someone 10 years older but who shuns tobacco, scientists said on Monday.

Select news items provided by Reuters Health
The Basics